Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved Johnson & Johnson's Risperdal for the treatment of schizophrenia and for the short-term treatment of bipolar mania in adolescents.
Subscribe to our email newsletter
Risperdal (risperidone) is already indicated in adults for the treatment of schizophrenia, manic symptoms of acute manic or mixed episodes associated with bipolar I disorder, and for the treatment of irritability associated with autistic disorder in ages 5-16 years.
The approval means that Risperdal can now be prescribed for the treatment of schizophrenia in adolescents ages 13-17 and for the short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder in children and adolescents ages 10-17.
J&J said that the approval is based on studies involving more than 430 adolescents, ages 13-17, in the treatment of schizophrenia and 160 children and adolescents, ages 10-17, for the short-term treatment of bipolar mania associated with manic or mixed episodes of bipolar I disorder.
Risperdal is marketed in the US by Janssen and promoted by McNeil Pediatrics, a division of McNeil-PPC.